Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.
A recent study published in the journal Nature evaluated differential autoreactivity to human and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteomes in SARS-CoV-2-infected children ...
Autoimmune diseases share the same core pathology despite their differing clinical manifestations: dysregulated B and T cell activity. B cells contribute to disease progression by secreting ...
The pathogenesis of multiple sclerosis (MS) has been tied to ineffective immune control of Epstein-Barr virus-driven autoimmune responses. Patients with MS are deficient in protective adaptive natural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results